DNA Ginkgo Bioworks Holdings, Inc.
8-K Current Report
Filed: February 27, 2026
Health Care
Biological Products, (No Diagnostic Substances)Ginkgo Bioworks Holdings, Inc. (DNA) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Ginkgo divesting its entire Biosecurity segment (Ginkgo Biosecurity, LLC) to Tower Biosecurity, Inc. — a full operational separation, not a partial sale
- • Deal structure: no cash received — Ginkgo takes ~20% equity stake in Tower Biosecurity on a fully diluted basis
Other Ginkgo Bioworks Holdings, Inc. 8-K Filings
Get deeper insights on Ginkgo Bioworks Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.